Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa

Xenobiotica

Volumn 42, Issue 10, 2012, Pages 989-1000

  Thelingwani, Roslyn S ^a,b   Dhansay, Kariema ^b   Smith, Peter ^b   Chibale, Kelly ^b   Masimirembwa, Collen M ^a,b  

^a African Institute of Biomedical Science and Technology (AIBST)   (Zimbabwe)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Docking simulations; Drugherb interactions; Inhibition; Metabolism; Natural products

Indexed keywords

3 CYANO 7 ETHOXYCOUMARIN; 7 ETHOXYCOUMARIN; ANTIINFECTIVE AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ETHOXYRESORUFIN; FRUTINONE A; FURAFYLLINE; PLANT EXTRACT; POLYGALA FRUTICOSA EXTRACT; TIABENDAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; METABOLIC CLEARANCE RATE; MOLECULAR DOCKING; NONHUMAN; PHENOTYPE; POLYGALA; POLYGALA FRUTICOSA;

ANTI-INFECTIVE AGENTS; CATALYTIC DOMAIN; CHROMONES; COUMARINS; CRYOPRESERVATION; CYTOCHROME P-450 CYP1A2; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; ISOENZYMES; KINETICS; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR DOCKING SIMULATION; NITRILES; OXAZINES; PLANT EXTRACTS; POLYGALA; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TIME FACTORS;

POLYGALA;

EID: 84865836634     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.681077     Document Type: Article

References (36)

1. Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637-1647.
2. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30-35.
3. Bailey DG, Malcolm J, Arnold O, Spence JD. (1998). Grapefruit juicedrug interactions. Br J Clin Pharmacol 46:101-110.
4. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
5. Bergeron C, Marston A, Wolfender J-L, Mavi S, Rogers C, Hostettmann K. (1997). Isolation of Polyphenols from Polygala gazensis and Liquid Chromatography-Mass Spectrometry of Related African Polygala Species. Phytochem Analysis 8:32-36.
6. Chavez ML, Jordan MA, Chavez PI. (2006). Evidence-based drug- herbal interactions. Life Sci 78:2146-2157.
7. Cho US, Park EY, Dong MS, Park BS, Kim K, Kim KH. (2003). Tightbinding inhibition by α-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta 1648:195-202.
8. DeLano WL. (2002). The PyMOL molecular graphics system. http://www.pymol.org.
9. de Visser SP, Shaik S. (2003). A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes. J Am Chem Soc 125:7413-7424.
10. Fugh-Berman A, Ernst E. (2001). Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52:587-595.
11. Fuhr U. (1998). Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 18:251-272.
12. Gelfand M, Mavi S, Drummond RB, Ndemera B. (1985). The Traditional Medical Practitioner in Zimbabwe. Gweru: Mambo Press.
13. Hostettmann K, Marston A, Ndjoko K, Wolfender JL. (2000). The potential of African plants as a source of drugs. Curr Org Chem 4:973-1010.
14. Houston JB, Carlile DJ. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
15. Izzo AA. (2005). Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19:1-16.
16. Izzo AA, Ernst E. (2009). Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777-1798.
17. Kiani J, Imam SZ. (2007). Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 6:33.
18. Klepser TB, Doucette WR, Horton MR, Buys LM, Ernst ME, Ford JK, Hoehns JD, Kautzman HA, Logemann CD, Swegle JM, Ritho M, Klepser ME. (2000). Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20: 83-87.
19. Kramer B, Rarey M, Lengauer T. (1999). Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37:228-241.
20. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. (2006). Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62:225-233.
21. Masimirembwa CM, Thompson R, Andersson TB. (2001). In vitro high throughput screening of compounds for favourable metabolic properties in drug discovery. Comb Chem High T Scr 4: 245-263.
22. Masimirembwa CM, Bredberg U, Andersson TB. (2003). Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515-528.
23. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. (2000). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502.
24. Mukinda JT, Eagles PF. (2010). Acute and sub-chronic oral toxicity profiles of the aqueous extract of Polygala fruticosa in female mice and rats. J Ethnopharmacol 128:236-240.
25. Paolo ERD, Hamburger MO, Stoeckli-Evans H, Rogers C, Hostettmann K. (1989). New Chromonocoumarin (= 6H, 7H-[1] Benzopyrano[4,3-b][1]benzopyran-6,7- dione) Derivatives from Polygala fruticosa BERG. Helvetica Chimica Acta 72:1455-1462.
26. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2007). Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348-14355.
27. Saxena A, Tripathi KP, Roy S, Khan F, Sharma A. (2008). Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation 3:198-204.
28. Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP. (1998). Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11:1048-1056.
29. Tarirai C, Viljoen AM, Hamman JH. (2010). Herb-drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol 6:1515-1538.
30. Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM. (2009). In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab Dispos 37:1286-1294.
31. Thompson TN. (2000). Early ADME in support of drug discovery: the role of metabolic stability studies. Curr Drug Metab 1:215-241.
32. Trott O, Olson AJ. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461.
33. Watt JM, Breyer-Brandwijk MG. (1962). The Medicinal and Poisonous Plants of Southern and Eastern Africa. Edingburgh and London: Livingstone Ltd.
34. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. (2003). Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440.
35. Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF. (2006). Drug-herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des 12:4649-4664.
36. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. (2003). Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35-98.